Mixed opioid agonist-antagonists
Mixed opioid
agonist-antagonists attempt to relieve pain whilereducing toxic effects and dependency. The
mixed opioid agonist-antagonists include:
·
buprenorphine
·
butorphanol
·
nalbuphine
·
pentazocine hydrochloride (combined with pentazocine lactate, naloxone,
aspirin, or acetaminophen).
Originally, mixed opioid agonist-antagonists appeared to have less abuse
potential than the pure opioid agonists. However, butor-phanol and pentazocine
have reportedly caused dependence. Also,patients with chronic pain who are
taking an opioid agonist shouldn’t take a mixed opioid agonist-antagonist with
it because of the risk of withdrawal symptoms.
Absorption of mixed opioid agonist-antagonists
occurs rapidly from parenteral sites. These drugs are distributed to most body
tissues and also cross the placental barrier. They’re metabolized in the liver
and excreted primarily by the kidneys, although more than 10% of a butorphanol
dose and a small amount of a penta-zocine dose are excreted in stool.
The exact mechanism of action of the mixed opioid
agonist-antagonists isn’t known. However, researchers believe that these drugs
weakly antagonize the effects of morphine, meperidine, and other opiates at one
of the opioid receptor sites, while exerting ag-onistic effects at other opioid
receptor sites.
Buprenorphine binds with receptors in the CNS,
altering percep-tion of and emotional response to pain through an unknown
mechanism. It seems to release slowly from binding sites, produc-ing a longer
duration of action than the other drugs in this class.
The site of action of butorphanol may be opiate
receptors in the limbic system (the part of the brain involved in emotion).
Like pentazocine, butorphanol also acts on
pulmonary circula-tion, increasing pulmonary vascular resistance (the
resistance in the blood vessels of the lungs that the right ventricle must pump
against). Both drugs also increase blood pressure and the work-load of the
heart.
Mixed opioid agonist-antagonists are used as
analgesia during childbirth and are also administered postoperatively.
Mixed opioid agonist-antagonists are sometimes
prescribed in place of opioid agonists because they have a lower risk of drug
de-pendence. Mixed opioid agonist-antagonists are also less likely to cause
respiratory depression and constipation, although they can produce some adverse reactions. (See Adverse reactions to opioid agonist-antagonists.)
Increased CNS depression and an
accompanying decrease in respiratory rate and depth may result if mixed opioid agonist antagonists are administered to patients taking
other CNS depressants, such as barbiturates and alcohol
Patients who abuse opioids shouldn’t receive mixed
opioid agonist-antagonists because these drugs
can cause symptoms of withdrawal.
Mixed opioid agonist-antagonists
are listed as pregnancy risk category C drugs; safety and use in breast-feeding
women haven’t been
established.
Related Topics
Privacy Policy, Terms and Conditions, DMCA Policy and Compliant
Copyright © 2018-2023 BrainKart.com; All Rights Reserved. Developed by Therithal info, Chennai.